Boundless Bio changes plans for cancer drug after toxicity issues
Boundless Bio has hit the reset button in the face of toxicity issues, nixing ongoing treatment arms in an early-stage cancer study in favor of …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
